Date: 2015-07-21
Type of information: Private placement
Company: Ultragenyx Pharmaceutical (USA - CA)
Investors:
Amount: $286.6 million
Funding type: private placement
Planned used: Ultragenyx Pharmaceutical intends to use the net proceeds of the offering to accelerate commercial launch preparation for Ace-ER, rhGUS, and KRN23 in the U.S. and other markets. Ultragenyx may also use a portion of the net proceeds to in-license, acquire, or invest in additional businesses, technologies, products, or assets, though Ultragenyx currently has no specific agreements, commitments, or understandings with respect to any material in-licensing or acquisition transactions. Finally, Ultragenyx may use any remaining net proceeds to invest in early-stage translational research, additional clinical activities, supportive general and administrative activities, hiring of additional personnel, and expansion of its facilities, as well as for additional working capital and other general corporate purposes.
Others: * On July 21, 2015, Ultragenyx Pharmaceutical, a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced the closing of its public offering of 2,530,000 shares of common stock at a price to the public of $120.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 330,000 additional shares of common stock. Morgan Stanley, J.P. Morgan and Cowen and Company acted as joint book-running managers for the offering. JMP Securities and Wedbush PacGrow acted as co-managers for the offering. * On July 15, 2015, Ultragenyx Pharmaceutical announced the pricing of its underwritten public offering of 2,200,000 shares of its common stock at a price to the public of $120 per share, before underwriting discounts. In addition, the company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 330,000 shares of the company\'s common stock at the public offering price, less the underwriting discount. The offering is expected to close on or about July 21, 2015, subject to satisfaction of customary closing conditions. * On July 14, 2015, Ultragenyx Pharmaceutical announced that it has commenced an underwritten public offering of up to $250,000,000 of shares of its common stock. In addition, the company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $37,500,000 of shares of common stock at the public offering price, less the underwriting discount. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
Therapeutic area: Rare diseases - Genetic diseases - Metabolic diseases
